First! Four specific antibodies of Leigh Pharmaceuticals were approved for clinical use.

According to CDE's official website, a clinical trial of the GNC-038 ivy antibody injection of Baillie Pharmaceuticals has applied for an implied license from the NMPA for the treatment of recurring or recurring non-Hodgkin's lymphoma (R/R NHL), recurring or resuscitated acute lymphoblastic leukemia (R/R ALL) and resuscitable/metastatic solid tumors.
is also the world's first clinically approved four-specific antibody, according to the company's official website.
founded in 1996,
's Berley Pharmaceuticals focuses on malignant tumors, developing innovative antibody drugs with breakthrough efficacy, antibody association drugs (ADCs), as well as children's drugs, anesthesia, severe illness, cardiovascular first aid drugs, etc.
GNC-038 is the first drug candidate to enter the clinic under its GNC (Guidance navigation and control, guided navigational control) platform, a "targeted immune" antibody for four specific structures that can target four antigens simultaneously and is clinically intended for the treatment of hematomas and solid tumors.
specifically, GNC-038 is a symmetrical four-specific antibody based on IgG in series of 3 scFv, of which 4-1BB, CD3 can collect and activate T cells, PD-L1 can lift immune escape, CD 19 can target tumors, this combination of PD-L1/4-1BB/CD3/CD19 can be seen as being based on CD3/CD19 dual resistance, further supplemented by PD-L1 blocking and 4-1BB path activation.
addition to GNC-038, a number of existing drug candidates on the BLY Pharmaceuticals GNC platform are in the declaration, preclinical and clinical research stages.
, SI-B001 and SI-B003 have entered clinical phase I, and SI-B001 is EGFR/HER3 dual resistance for the treatment of local late-stage or metastatic endostropheric tumors, including esophageal squamous cancer and pulmonary squamous cancer Three-yin breast cancer, head and neck squamous cancer, colorectal cancer, si-B003 target has not been disclosed, for the treatment of local late stage, recurrence or metastatic solid tumors, including renal cell carcinoma, colorectal cancer, melanoma, non-small cell lung cancer, urethra cancer and so on.
since monoclonal antibodies such as PD-1/PD-L1 led the tumor immunotherapy boom, the development of dual-characteristic antibodies, trisexual antibodies and multisexual antibodies has also emerged.
two specific antibodies, three are currently on the market: Fresenius's Removab, Amsen's Blincyto and Roche's Hemlibra.
hundreds of dual-resistance molecules are currently being evaluated in clinical trials and are expected to see a full-scale outbreak in the coming years, according to a review of the two-resistance published last year in Nature Reviews Drug Discovery.
At present, there are a number of domestic enterprises into the clinical, from the target point of view, PD-1/PD-L1, CTLA-4 and HER2 as the target of the majority of projects, in the BCMA, 4-1BB, C-MET and other targets have also been laid out.
, abroad, Sanofi's CD38/CD28/CD3 trisexual antibody SAR442257 launched a clinical study in May this year for patients with recurring refractic multiple myeloma and non-Ho Chikin lymphoma patients, who are scheduled to join 57 patients, are expected to complete by 2024, while Roche builds more compact CD3 triso-heteroant antibodies through Contorsbody, which helps form immune synapses between T-cells and tumor cells.
Dragonfly's TAA/CD16/NKG2D trisexual antibody TriNKET and Innate Pharma's TAA/CD 16/NKp46 trisexual antibody NKCE technology focus on tumor immunity of NK cells.
, Keystone Pharmaceuticals reached an agreement with Numab Therapeutics to obtain PD-L1/4-1BB/HSA iii-specific antibody ND021; Zee-Sein Pharmaceuticals and its holding subsidiary Gensun Biopharma reached an agreement to obtain three-specific antibody ZGGS001; and Sansheng Guojian entered into a partnership with Numab to develop and commercialize a range of new multisexual antibodies for cancer treatment.
name source: Medical Valley network !-- content display end -- !-- determine whether the login ends.